325 related articles for article (PubMed ID: 34218257)
1. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Hongo T; Yamamoto H; Jiromaru R; Yasumatsu R; Kuga R; Nozaki Y; Hashimoto K; Matsuo M; Wakasaki T; Tamae A; Taguchi K; Toh S; Masuda M; Nakagawa T; Oda Y
Mod Pathol; 2021 Nov; 34(11):1966-1978. PubMed ID: 34218257
[TBL] [Abstract][Full Text] [Related]
2. HPV-related Sinonasal Carcinoma: Clinicopathologic Features, Diagnostic Utility of p16 and Rb Immunohistochemistry, and EGFR Copy Number Alteration.
Jiromaru R; Yamamoto H; Yasumatsu R; Hongo T; Nozaki Y; Hashimoto K; Taguchi K; Masuda M; Nakagawa T; Oda Y
Am J Surg Pathol; 2020 Mar; 44(3):305-315. PubMed ID: 31743130
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Significance of EGFR Mutation and HPV Infection in Sinonasal Squamous Cell Carcinoma.
Hongo T; Yamamoto H; Jiromaru R; Nozaki Y; Yasumatsu R; Hashimoto K; Yoneda R; Sugii A; Taguchi K; Masuda M; Nakagawa T; Oda Y
Am J Surg Pathol; 2021 Jan; 45(1):108-118. PubMed ID: 32868526
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Therapeutic Implications of Immune Classification by CD8
García-Marín R; Reda S; Riobello C; Cabal VN; Suárez-Fernández L; Vivanco B; Álvarez-Marcos C; López F; Llorente JL; Hermsen MA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203211
[TBL] [Abstract][Full Text] [Related]
5. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
[TBL] [Abstract][Full Text] [Related]
6. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
8. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
9. Correlation of immune makers with HPV 16 infections and the prognosis in oropharyngeal squamous cell carcinoma.
Zhu Y; Zhu X; Diao W; Liang Z; Gao Z; Chen X
Clin Oral Investig; 2023 Apr; 27(4):1423-1433. PubMed ID: 36884083
[TBL] [Abstract][Full Text] [Related]
10. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
13. Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
Wu S; Shi X; Wang J; Wang X; Liu Y; Luo Y; Mao F; Zeng X
Front Immunol; 2021; 12():561793. PubMed ID: 33717059
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
[TBL] [Abstract][Full Text] [Related]
19. Uncovering PD-L1 and CD8
Chen J; Gu P; Wu H
Biomed Res Int; 2020; 2020():8164365. PubMed ID: 32884946
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
